Startseite
Diese Website ist für medizinisches Fachpersonal bestimmt.

Sich wandelnde Paradigmen in der Lungenkrebsbehandlung: Modul 3 – Klinische Evidenz zu bispezifischen Antikörpern

Teilen

Beschreibung

Diese Fortbildungsmaßnahme wird durch einen unabhängigen Bildungszuschuss der BioNTech-BMS Alliance unterstützt. Dieses Online-Fortbildungsprogramm richtet sich an medizinische Fachkräfte weltweit.

Begleiten Sie Dr. Edward Garon, der die zunehmende Bedeutung der Präzisionsmedizin beim nicht-kleinzelligen Lungenkarzinom (NSCLC) erläutert. Dieses von Experten geleitete Microlearning-Modul beleuchtet die Biomarker, die heute die Therapieentscheidung bestimmen – von therapierbaren genomischen Alterationen bis hin zu Immuntherapie-Biomarkern wie der PD-L1-Expression und der Tumormutationslast (Tumor Mutational Burden, TMB). Darüber hinaus werden neue molekulare Biomarker vorgestellt, die zukünftig zu einer noch präziseren, personalisierten Therapiestrategie beitragen könnten.

Sie möchten den Inhalt lieber lesen? Hier finden Sie unsere Zusammenfassung der wichtigsten klinischen Erkenntnisse.

Highlights der Fortbildung

  • Verfolgen Sie die Entwicklung der Präzisionsmedizin beim NSCLC – von einer histologiebasierten Therapieentscheidung hin zu einer biomarkergestützten Behandlungsstrategie.
  • Verstehen Sie den klinischen Stellenwert etablierter Biomarker, einschließlich therapierbarer genomischer Alterationen, der PD-L1-Expression und der Tumormutationslast (TMB), bei der Auswahl der optimalen Therapie.
  • Verschaffen Sie sich einen Überblick über die Evidenz zu Immuntherapie-Biomarkern und deren Einfluss auf die Patientenselektion sowie die Behandlungsergebnisse.
  • Lernen Sie neue molekulare Biomarker kennen, darunter STK11- und KEAP1-Mutationen, sowie deren potenzielle Rolle bei der Weiterentwicklung zukünftiger personalisierter Therapiestrategien.

Zielgruppe

Diese Fortbildungsmaßnahme richtet sich an Fachärztinnen und Fachärzte für Hämatologie und Onkologie sowie Pneumologie, Advanced Practice Nurses, Physician Associates, Apothekerinnen und Apotheker, Pflegefachpersonen und weitere medizinische Fachkräfte, die Patientinnen und Patienten mit Lungenkarzinomen – einschließlich des nicht-kleinzelligen Lungenkarzinoms (NSCLC) und des kleinzelligen Lungenkarzinoms (SCLC) – betreuen.

Referent

Edward Garon, MD, ist Direktor des Thoracic Oncology Program am Jonsson Comprehensive Cancer Center der University of California, Los Angeles (UCLA), sowie Associate Professor an der UCLA. Als international anerkannter Thoraxonkologe liegen seine klinischen und wissenschaftlichen Schwerpunkte auf der Behandlung des Lungenkarzinoms, der Entwicklung neuer Biomarker sowie der Konzeption innovativer klinischer Studien. Dr. Garon hat zahlreiche nationale und internationale klinische Studien der Phasen I bis III geleitet, darunter mehrere Studien, die zur Zulassung neuer onkologischer Therapien sowie eines Companion Diagnostics beigetragen haben.

Offenlegung von Interessenkonflikten

Gemäß den Richtlinien des European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) haben alle Referierenden und Moderierenden potenzielle Interessenkonflikte offengelegt bzw. erklärt. Die wissenschaftliche Leitung trägt die Verantwortung dafür, dass alle für diese Fortbildungsmaßnahme relevanten Interessenkonflikte den Teilnehmenden vor Beginn der Fortbildung transparent dargelegt werden.

Dr. Edward Garon, Referent dieser Fortbildungsmaßnahme, hat innerhalb der vergangenen 36 Monate finanzielle Beziehungen zu den folgenden Unternehmen offengelegt:

Beratung und/oder Mitgliedschaft in Advisory Boards: AbbVie; AstraZeneca; Arrivent; Bayer; Bicycle; Black Diamond Therapeutics; BridgeBio; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; GSK; Gilead; Hexagon; I-Mab; IO Biotech; iTeos; Merck; Nuvalent; Oxford Bio; Pfizer; Regeneron; Samsung; Sanofi; Servier; Strata; Synthekine; Transcode; Verastem.

Forschungsförderung/Forschungsunterstützung (Institution): ABL-Bio; Arrivent; AstraZeneca; Bayer; BridgeBio; Bristol Myers Squibb; Daiichi Sankyo; Eli Lilly; Genentech; Gilead; Iovance Biotherapeutics; Merck; Novartis; Prelude; Regeneron; Synthekine; TILT Biotherapeutics.

Geistiges Eigentum: Motif Neoepitopes for Cancer Immunotherapy.

Die Mitarbeitenden von MedAll sowie alle an der Planung und Begutachtung beteiligten Personen haben keine relevanten finanziellen Beziehungen zu Unternehmen offenzulegen.

Informationen zur EBAC®-Akkreditierung

Diese Fortbildungsmaßnahme wurde gemäß den Akkreditierungsanforderungen und Richtlinien des European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) entwickelt und umgesetzt.

MedAll ist seit 2025 ein von EBAC akkreditierter Fortbildungsanbieter. Das European Board for Accreditation of Continuing Education for Health Professionals (EBAC) akkreditiert medizinische Fortbildungsprogramme für die internationale Fachgemeinschaft.

Dieses Programm wurde von EBAC® mit 15 Minuten anrechenbarer Fortbildungszeit akkreditiert.

Gemäß den EBAC-Richtlinien haben alle Referierenden und Vorsitzenden potenzielle Interessenkonflikte offengelegt bzw. erklärt. Die wissenschaftliche Leitung stellt sicher, dass alle für die Fortbildungsmaßnahme relevanten Interessenkonflikte den Teilnehmenden vor Beginn der Fortbildung mitgeteilt werden.

EBAC® unterhält Vereinbarungen über die gegenseitige Anerkennung der inhaltlichen Gleichwertigkeit mit dem Accreditation Council for Continuing Medical Education (ACCME) in den USA sowie dem Royal College of Physicians and Surgeons of Canada.

Im Rahmen einer Vereinbarung zwischen EBAC® und der American Medical Association können Ärztinnen und Ärzte EBAC® External CME Credits in AMA PRA Category 1 Credits™ umwandeln. Informationen zum Umrechnungsverfahren finden Sie auf der Website der AMA. Angehörige anderer Gesundheitsberufe können über die AMA eine Teilnahmebescheinigung für Fortbildungsmaßnahmen erhalten, die für eine Umwandlung in AMA PRA Category 1 Credit™ geeignet sind.

Das Accreditation Council for Continuing Medical Education (ACCME) und das Royal College of Physicians and Surgeons of Canada erkennen die Gleichwertigkeit ihrer Akkreditierungssysteme mit EBAC an.

EBAC® ist Mitglied der International Academy for CPD Accreditation (IACPDA) sowie Partnermitglied der International Association of Medical Regulatory Authorities (IAMRA).

So erhalten Sie Ihre EBAC®-Fortbildungspunkte

Um Ihre CME-Punkte sowie Ihr Teilnahmezertifikat zu erhalten, absolvieren Sie bitte die gesamte Fortbildungsmaßnahme und füllen Sie anschließend die Evaluation aus. Nach erfolgreichem Abschluss erhalten Sie einen Link zu Ihrem Zertifikat.

Teilnahmegebühren

Die Teilnahme an dieser Fortbildungsmaßnahme ist kostenfrei.

Diese Fortbildungsmaßnahme ist vom 22. Juli 2026 bis zum 14. Juli 2027 verfügbar.

Geschätzte Bearbeitungszeit: 15 Minuten.

Ähnliche Communities

Alle anzeigen

Ähnliche Veranstaltungen und On-Demand-Videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

I'm Edward Garin, uh, and I will be presenting now on precision patient selection. Um, this is, of course, going to focus on patients with non-small cell lung cancer. Before we begin, these are our disclosures. We will begin with a polling question. Uh, this is a 60-year-old patient with non-small cell lung cancer, um, who has a tumor with PDL-1 expression of 0%. Uh, comprehensive genomic profiling reveals a very high non-synonymous tumor mutation burden. Um, we're discussing the rationale for utilizing immunotherapy despite the negative PDL-1 status. And Um, based on the foundational discovery cohorts evaluating the genomic landscape of non-small cell lung cancer, uh, from Nya Rizvi and colleagues, uh, how does a non-synonymous, uh, tumor mutation burden correlate with clinical outcomes for patients treated with a PD1 pathway blockade? And the choices here are A, uh, high mutational burden is strongly associated with improved progression-free survival. Uh, B, high mutational burden only improves overall survival if the patient also has an EGFR mutation. C, high mutational burden is associated with worse PFS due to hyperprogression. Or D, high mutational burden has no correlation with progression-free survival. It only predicts toxicity. So, uh, standard of care for many years, uh, going into the mid 2000s was, uh, at least in the United States, a combination of carboplatin and paclitaxel, um, in this, uh, figure here, this is the pink bar, uh, noted as PC. Um, there was Uh, uh, what at the time was considered to be a major advance, uh, the addition of bevacizumab. Bevacizumab is a monoclonal antibody targeting VEGF. And, um, you can see in the dash blue line, the combination of bevacizumab, paclitaxel, and carboplatin. Uh, showed an improvement in overall survival. You can see the outcome data here with respect to response rate, um, overall survival, as well as progression-free survival, all favoring, uh, the bevacizumab, uh, arm. The, um, the curves eventually do appear to come together at the end. Um, but at least for the field psychologically, this was also a big advance is, in, in that it was the first time. Um, that we had really shown survival over a year, um, at that point in patients with, uh, stage 4 non-small cell lung cancer. Um, although it's not necessarily exactly what we think of when we think of, uh, precision medicine. Um, I think it's important to note that, uh, one thing that did shape the field is really two medicines, uh, that really separated the management of, uh, squamous cell disease from non-squamous, non-small cell lung cancer. One was the data I just showed about bevacizumab. Bevacizumab. Uh, when it was utilized in patients with squamous cell carcinoma, had an unacceptable rate of, uh, pulmonary hemorrhage, which unfortunately, in some cases was fatal. Um, and the other data set really was, uh, this study, which, uh, looked at cisplatin and Pemitrex, in which at the time was a fairly new chemotherapeutic versus cisplatin and, uh, gemcitabine. And what you can see here is that there were clear benefits with the pemitrexate, uh, arm doing, doing better in, in the adenocarcinoma. Whereas, um, really in the squamous, uh, it looked like the gemcitabine arm was Uh, a better arm. Then we saw what I would argue is real, uh, improvements in, uh, targeted therapy. But initially, we actually didn't know who the targets were. Um, this is a data set I was involved with years ago. And I just think graphically shows very nicely the outcome. You can see, um, On the left, you can see a patient who is, uh, you know, has extensive disease. You can see the results in the middle figure over here on the left. Um, actually, only a couple of weeks into therapy, um, followed by, by, by a couple of months, really, uh, significant improvement overall. Um, interestingly, this was with, uh, an EGFR inhibitor. And there was a time when there was really uh sort of uh quite considerable discussion about who are the patients who benefited from uh an EGFR inhibitor. There were some people who felt that it was really best assessed on clinical characteristics, some who were looking at EGFR, uh, gene copy number, like what is done with, uh, with the related gene HERR2. Um, uh, and then that was really answered by, by Tony Mock and colleagues. Um, this study enrolled exclusively in East Asia. Patients had to have smoked less than 100 cigarettes per day. And what you can see here is if you look at the progression-free survival, when comparing, uh, dofinib in green to chemotherapy in yellow, On the left, you see these very bizarre progression-free survival curves that cross, uh, sort of right in the middle. And when you look at the right, you see why those curves crossed. And, um, they had, uh, sort of correlative data on many of the patients. And you can see that, uh, in the patients who had an EGFR mutation, the gefitinib, uh, the EGFR inhibitor in green, performed much better than chemotherapy. However, in the patients who did not have an EGFR mutation, Uh, the jafitinibine green was very, a very poor, uh, agent for treatment. And that is sort of two separate populations is what contributed to the overall sort of strange appearing progression for your survival curves. Um, EGFR was sort of the first, but you can see there were many different, um, of these. I list this as sort of a historical data set. Um, this was the Lung Cancer Mutation Consortium, which really broke, uh, patients with, uh, different Uh, mutations and adenocarcinoma into different sort of eye pieces here. Um, and, and the, this pie, uh, that you see, which separates different populations have become more refined over time. Um, and there even have been additional mutations that have been discovered. But these looking for driver mutations in many respects has revolutionized the management of non-small cell lung cancer. Um, well, the targeted therapy, uh, revolution was sort of, uh, ongoing. Another revolution in terms of selecting patients was coming in, uh, immunotherapy. Immunotherapy, um, is in many respects, a very different approach when compared to, um, sort of what we typically see for these targetable mutations, where we will have a tyrosine kinase inhibitor that directly blocks signaling. Um, but in this case, in many respects, the, the, the biomarkers still end up, uh, driving things. Here, you can see the original design of the keynote 001 study, which helped define the PDL1 biomarker for pembrolizumab. You can see as part of that, patients really were divided into three separate groupings. Those with PD1 expression in less than 1% of their cells, those with expression in 1 to 49% of their cells, and those with expression in at least half of their cells. Um, obviously, expression here is denoted in brown. The cutoff as part of that study was 50%. But what you can see is it's sort of a stepwise curve. Here, you see, um, in purple, the prevalence of PDL1 expression in all screened patients. Um, and then in blue, um, the response rate amongst those patients. And as you can see, um, by, by the, the blue here, um, the higher the patient's PDL one expression, the greater the likelihood that the patient would have a benefit from, uh, PD one inhibition. That was seen also with respect, uh, not only to response rate, but also progression-free survival shown here with the greater than 50% patients doing significantly better. And, uh, this also played out with respect to overall survival with those with high expression doing particularly well. At the time when, uh, when this was ongoing, people wouldn't Uh, weren't that excited about showing this data cause there was a lot of, uh, controversy about the PDL1 biomarker. But here you can see it compared to, uh, crizotinib, uh, in both, uh, on the left, AL gene rearranged, non-small cell lung cancer, and on the right, ROS1 gene rearranged, uh, non-small cell lung cancer. And as you can see, um, although pembrolizumab, uh, was not, the, the PDL1, uh, 50% or greater was not quite as predictive. Um, still, there are a lot of similarities between these curves. Um, and the time has sort of proven that this is a, uh, biomarker that has sort of, uh, continued to be part of our management. So it is not the only biomarker that we look at. Um, obviously, across histologies, people have looked at microsatellite instability. That tends not to be seen much very often with lung cancer. But one of the things that became very clear early on, um, this is data from the TCGA. And if you look, um, this is showing the number of mutations, uh, per tumor. And what you can see is melanoma on the right, followed by lung squamous cell, then lung adeno, um, then bladder. In many respects, it looks like you are going through, um, the, the approvals for PD1 inhibitors, uh, or PDL1 inhibitors. And, um, we were able to be part of this evaluation, uh, Naya Risby, Tim Chan, uh, Matt Hellman.